Rofecoxib did not slow progression of dementia in patients with established Alzheimer's disease

Evidence-Based Medicine

Volumn 9, Issue 5, 2004, Pages 148-

  Reines, S A ^c   Block, G A ^c   Morris, J C ^c   Lines, Chris ^a   Riggs, Garrett ^b   Holloway, Robert ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB;

ALZHEIMER DISEASE; CAREGIVER; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DISEASE COURSE; DRUG COST; DRUG SELECTIVITY; ENCEPHALITIS; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; GASTROINTESTINAL DISEASE; HEART FAILURE; HOSPITAL ADMISSION; HUMAN; INTERVIEW; PATHOPHYSIOLOGY; RATING SCALE; RISK BENEFIT ANALYSIS; RISK REDUCTION; SCORING SYSTEM; SHORT SURVEY;

EID: 19644370799     PISSN: 13565524     EISSN: None     Source Type: Journal    
DOI: 10.1136/ebm.9.5.148     Document Type: Short Survey

References (2)

1. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003;289:2819-26.
2. Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004;363 1751-6.